Cover Image
市場調查報告書

EpiCast Report:糖尿病黃斑部水腫的流行病學預測

EpiCast Report: Macular Edema - Epidemiology Forecast to 2026

出版商 GlobalData 商品編碼 312372
出版日期 內容資訊 英文 42 Pages
訂單完成後即時交付
價格
Back to Top
EpiCast Report:糖尿病黃斑部水腫的流行病學預測 EpiCast Report: Macular Edema - Epidemiology Forecast to 2026
出版日期: 2017年11月01日 內容資訊: 英文 42 Pages
簡介

黃斑部水腫(ME),是因為在視網膜擔任中心視野之黃斑的肥厚、腫脹(水腫)而發生。全球主要7個國家(美國、法國、德國、義大利、西班牙、英國、日本)的糖尿病黃斑部水腫(DME)的發病數量,預計從2013年的922,492件,今後10年達到1,238,301件,增加34.2%。

本報告提供全球主要7個國家的糖尿病黃斑部水腫(DME)調查分析、疾病的背景、危險因素和共生病症、全球趨勢、流行病學預測等相關的系統性資訊。

第1章 目錄

第2章 簡介

第3章 流行病學

  • 疾病的背景
  • 危險因素和共生病症
  • 全球趨勢
    • 美國
    • 主要5個國家
    • 日本
  • 預測手法
    • 利用之資訊來源
    • 未利用之資訊來源
    • 預測的前提條件與手法 - 糖尿病和確診的患者數
    • 預測的前提條件與手法 - 糖尿病視網膜病變和確診的患者數
    • 預測的前提條件與手法 - 糖尿病視網膜病變和確診的患者數中,糖尿病黃斑部水腫(DME)和確診的患者數
    • 預測的前提條件與手法 - 次於視網膜分支靜脈阻塞症(BRVO)、視網膜中心靜脈閉塞症(CRVO),黃斑部水腫的整體患者數
  • 黃斑部水腫的流行病學預測
    • 糖尿病視網膜病變和確診的患者數中,DME和確診的患者數
    • 糖尿病視網膜病變和確診的患者數中,DME和確診的患者數:各年齡
    • 糖尿病視網膜病變和確診的患者數中,DME和確診的患者數:性別
    • 接著BRVO,ME的整體患者數
    • 接著BRVO,ME的整體患者數:各年齡
    • 接著BRVO,ME的整體患者數:性別
    • 接著CRVO,ME的整體患者數
    • 接著CRVO,ME的整體患者數:各年齡
    • 接著CRVO,ME的整體患者數:性別
  • 議論
    • 流行病學預測相關考察
    • 分析的限制
    • 分析的優勢

第4章 附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHCER169-17

Macular edema (ME) is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as diabetic macular edema (DME). The risk for ME is also higher in patients with retinal vein occlusion (RVO), which consists of two types: branch retinal vein occlusion (BRVO) and central retinal vein occlusion (CRVO).

GlobalData's epidemiological analysis is supported by the use of country-specific prevalence data from epidemiological studies published in peer-reviewed journals. GlobalData epidemiologists used uniform methodology across the markets to forecast the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population and the total prevalent cases of ME following BRVO and CRVO, to allow for a meaningful comparison of the disease populations across these markets.

In the 7MM, GlobalData epidemiologists forecast that the diagnosed prevalent cases of DME in the diagnosed retinopathy population will grow by 31.29% over the forecast period, at an Annual Growth Rate (AGR) of 3.13%, from 980,030 cases in 2016 to 1,286,637 cases by 2026. The total prevalent cases of ME following BRVO in the 7MM increased from 307,341 total prevalent cases in 2016 to 347,397 total prevalent cases in 2026. The total prevalent cases of ME following CRVO in the 7MM increased from 125,326 total prevalent cases in 2016 to 149,226 total prevalent cases in 2026, at an AGR of 1.91% during the forecast period.

Scope

  • The Macular edema (ME) EpiCast Report provides an overview of the risk factors, comorbidities, and the global and historical trends for ME in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the diagnosed prevalent cases of DME among the diagnosed diabetic retinopathy population, diagnosed prevalent cases of clinically significant DME among the diagnosed DME population, and the total prevalent cases of ME following BRVO and CRVO segmented by sex and age (ages 20 years and older) in these markets.
  • The ME epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The ME EpiCast report will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global ME market.
  • Quantify patient populations in the global ME market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for ME therapeutics in each of the markets covered.
  • Understand magnitude of ME population by age and sex.

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 4
  • 1.2 List of Figures 4

2 Executive Summary 5

  • 2.1 Related Reports 8
  • 2.2 Upcoming Reports 8

3 Epidemiology 9

  • 3.1 Disease Background 9
  • 3.2 Risk Factors and Comorbidities 10
  • 3.3 Global and Historical Trends 10
  • 3.4 Forecast Methodology 11
    • 3.4.1 Sources 11
    • 3.4.2 Forecast Assumptions and Methods 16
    • 3.4.3 Diagnosed Prevalent Cases of T2D 16
    • 3.4.4 Diagnosed Prevalent Cases of T1D 20
    • 3.4.5 Diagnosed Prevalent Cases of Diabetic Retinopathy 20
    • 3.4.6 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 21
    • 3.4.7 Diagnosed Prevalent Cases of Clinically significant DME Among the Diagnosed DME Population 22
    • 3.4.8 Total Prevalent Cases of BRVO and CRVO 23
    • 3.4.9 Total Prevalent Cases of ME following BRVO and CRVO 23
  • 3.5 Epidemiological Forecast for Macular Edema (2016-2026) 25
    • 3.5.1 Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 25
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 26
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 27
    • 3.5.4 Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed the DME Population 28
    • 3.5.5 Total Prevalent Cases of ME following BRVO 29
    • 3.5.6 Age-Specific Total Prevalent Cases of ME Following BRVO 30
    • 3.5.7 Sex-Specific Total Prevalent Cases of ME Following BRVO 31
    • 3.5.8 Total Prevalent Cases of ME following CRVO 32
    • 3.5.9 Age-Specific Total Prevalent Cases of ME Following CRVO 33
    • 3.5.10 Sex-Specific Total Prevalent Cases of ME Following CRVO 34
  • 3.6 Discussion 35
    • 3.6.1 Epidemiological Forecast Insight 35
    • 3.6.2 Limitations of Analysis 35
    • 3.6.3 Strengths of Analysis 36

4 Appendix 37

  • 4.1 Bibliography 37
  • 4.2 About the Authors 40
    • 4.2.1 Epidemiologist 40
    • 4.2.2 Reviewers 40
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology 41
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy 41
  • 4.3 About GlobalData 42
  • 4.4 Contact Us 42
  • 4.5 Disclaimer 42

List of Tables

1.1 List of Tables

  • Table 1: Risk Factors and Comorbidities for DME 10
  • Table 2: 7MM, Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population, 2016 11
  • Table 3: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026. 25
  • Table 4: 7MM, Diagnosed Prevalent Cases of Clinically Significant DME Among the Diagnosed DME Population, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 28
  • Table 5: 7MM, Total Prevalent Cases of ME following BRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 29
  • Table 6: 7MM, Total Prevalent Cases of ME following CRVO, Both Sexes, Ages ≥20 Years, N, Selected Years 2016-2026 32

List of Figures

1.2 List of Figures

  • Figure 1: 7MM, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 6
  • Figure 2: 7MM, Total Prevalent Cases of ME Following BRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 7
  • Figure 3: 7MM, Total Prevalent Cases of ME Following CRVO, Both Sexes, Ages ≥20 Years, N, 2016 and 2026 8
  • Figure 4: 7MM, Sources Used and Not Used, Diagnosed Prevalent Cases of T2D Among the General Population 12
  • Figure 5: 7MM, Sources Used, Diagnosed Prevalent Cases of T1D Among the General Population 13
  • Figure 6: 7MM, Sources Used, Diagnosed Prevalent Cases of Diabetic Retinopathy Among the Diagnosed Diabetes Population 13
  • Figure 7: 7MM, Sources Used, Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population 14
  • Figure 8: 7MM, Sources Used, Diagnosed Prevalent Cases of Clinically-Significant DME Among the Diagnosed Diabetic Retinopathy Population 14
  • Figure 9: 7MM, Sources Used , Total Prevalent Cases of BRVO and CRVO Among the General Population 15
  • Figure 10: 7MM, Sources Used, Total Prevalent Cases of ME following BRVO 15
  • Figure 11: 7MM, Sources Used, Total Prevalent Cases of ME following CRVO 16
  • Figure 12: 7MM, Age-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Both Sexes, N, 2016 26
  • Figure 13: 7MM, Sex-Specific Diagnosed Prevalent Cases of DME Among the Diagnosed Diabetic Retinopathy Population, Ages ≥20 Years, N, 2016 27
  • Figure 14: 7MM, Age-Specific Total Prevalent Cases of ME Following BRVO, Both Sexes, N, 2016 30
  • Figure 15: 7MM, Sex-Specific Total Prevalent Cases of ME following BRVO, Ages ≥20 Years, N, 2016 31
  • Figure 16: 7MM, Age-Specific Total Prevalent Cases of ME Following CRVO, Both Sexes, N, 2016 33
  • Figure 17: 7MM, Sex-Specific Total Prevalent Cases of ME following CRVO, Ages ≥20 Years, N, 2016 34
Back to Top